Conventional X-ray mammography has low diagnostic sensitivity for women with dense breasts.
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Main text
The key to good prognosis of breast cancer is early detection. Currently, X-ray mammography is the gold standard for breast cancer screening and has been shown to reduce mortality from breast cancer. 1 Nevertheless, it is well established that diagnostic sensitivity of mammography is greatly reduced in women with dense breasts, who are about 50% of the screening population. 2 The sensitivity decreases from a level of 87% in women with less dense breasts to only 30-62% in women with dense breasts. [3] [4] When mammography is used alone as a screening tool, decreased sensitivity may lead to delayed diagnosis, more advanced stage and reduced survival. Moreover, women with dense breasts have a three-fold higher risk of developing breast cancer, independent of issues related to screening. 5 Therefore, alternative screening tools are being developed for this population.
Contrast-enhanced imaging techniques such as magnetic resonance imaging (MRI), dual-energy mammography (DEM), computed tomography (CT), and near-infrared fluorescence (NIRF) imaging have emerged to improve breast cancer detection for women with dense breasts. These imaging modalities each use contrast agents to highlight breast abnormalities and overcome the masking effect from increased breast density. Screening breast MRI requires gadolinium-based contrast agents; however, free gadolinium ions can cause nephrotoxicity in patients with renal disease [6] [7] and gadolinium deposits in the brain, with unknown effects. [8] [9] [10] [11] Similarly, contrast-mediated nephropathy as well as patient allergic reactions are risks posed by iodinated contrast agents, such as iopamidol, which are commonly used in CT and DEM. [12] [13] [14] Moreover, iodinated agents produce suboptimal contrast especially in the case of DEM. 15 Improved contrast agents are needed for tumor detection and characterization with these imaging modalities.
Nanoparticles have potential as safe and effective contrast agents for numerous breast imaging modalities. [15] [16] [17] [18] [19] [20] [21] For example, iron oxide nanoparticles (IO-NP) provide contrast in T 2 -or Page 3 of 40 Nanoscale T 2 * -weighted MRI that can be used for distinguishing lesions from normal tissues. 22 Silver nanoparticles have recently been identified to produce stronger contrast than iodinated agents in DEM. 15, 21 In addition, silver nanoparticles should provide CT contrast that is comparable to iodine as silver's k-edge at 25.5 keV allows for strong attenuation of lower energy X-rays. 20 However, to form stable and safe silver-based nanoparticles, a high percentage of gold inclusion was required, 20 resulting in a significant material cost. To overcome this cost issue, we herein propose silver sulfide nanoparticles (Ag 2 S-NP) whose ultralow solubility constant (K sp = 6.3 x 10 -50 ), 23 we hypothesized, would limit the release of silver ions, providing good biocompatibility, but with low material costs (the cost of sulfur is about $0.09/kg). 24 Combining Ag 2 S-NP, IO-NP and a NIRF fluorophore creates a multimodality agent for multiple imaging techniques. This will allow a safe and flexible screening option for intermediate and high risk patients, including women with dense breasts who need additional screening for improved sensitivity over conventional mammography. To our knowledge, the development of a multimodal contrast agent specific for breast cancer screening has rarely been explored. The integration of Ag 2 S-NP, IO-NP and NIRF fluorophores into one platform has not previously been reported and provides functionalities for four different breast imaging modalities. This probe is uniquely designed to address issues related to current contrast agents. Moreover, the use of Ag 2 S-NP as contrast agents for X-ray imaging has not previously been reported and there is only a handful of examples of novel contrast materials developed specifically for mammography.
In this study, we report a novel "all- 
Results and discussion
Synthesis and characterization of AION
To synthesize AION, hydrophobic Ag 2 S-NP were first synthesized via a thermal decomposition single-source precursor approach adapted from previous reports. [25] [26] This reaction resulted in dodecanethiol-coated Ag 2 S-NP with an average core diameter of 4.7 ± 1.2 nm (Fig. 1B) . The as-prepared Ag 2 S-NP, along with oleic-acid coated 10 nm IO-NP ( Fig. 1C) and the lipophilic DiR fluorophore were encapsulated in the hydrophobic core of micelles biocompatibility, as well as to deter opsonization and thus facilitate accumulation within the tumor via the enhanced permeability and retention (EPR) effect. [27] [28] [29] As a result, we did not observe significant changes in particle diameter (<5%) as determined by DLS when incubated in PBS containing 10% fetal bovine serum at 37 °C for 24 hours, proving its robust stability in physiological conditions.
The average core size and hydrodynamic diameter of AION were 88 ± 22 nm and 114 ± 2.7 nm as determined by TEM ( Fig. 1D and E) and DLS, respectively. A polydispersity index of 0.161 was measured by DLS. The zeta potential of AION was found to be -42.5 ± 0.8 mV,
indicating good stability towards coagulation or flocculation. The morphology of AION is indicated by SEM ( Fig. S1 ). The EDX spectrum ( Fig. S2 ) showed that AION have the expected 2:1 Ag:S stoichiometry and contain more silver than iron, which is consistent with the mass ratio used in the synthesis. A representative EDX line scan across a single AION particle is provided 7 in Fig. S3 , which confirms the inclusion of both iron and silver within the same nanoparticle.
AION have a broad UV-visible absorption band that is typical of Ag 2 S-NP with an absorption peak at 748 nm, which corresponds to the excitation wavelength of DiR ( Fig. S4 ). 26 Under excitation at 748 nm, a sharp fluorescence emission peak at 780 nm was observed that is again typical of DiR (Fig. S4 ). Both absorption and emission peaks of AION lie within the NIR region (650-900 nm), where tissue is more transparent to light. 30 Although silver nanoparticles have been widely used in many consumer products, release of silver ions from these nanoparticles could pose a safety risk. We therefore evaluated the silver ion leaching potential of AION and a control silver nanoparticle (AgNP) by incubating them in two different media (DI water and citrate buffer at pH 5.5) at 37°C. AgNP were synthesized using a protocol consistent with AION preparation except for the incorporation of DT-coated elemental silver nanoparticles (5 nm in core diameter) instead of Ag 2 S-NP. 31 A TEM image of AgNP is shown in Fig. S5 . Citrate buffer with a slightly acidic pH was used to simulate lysosomal fluid and the tumor microenvironment for the following reasons: 1) most silver nanoparticles are found in lysosomes after phagocytosis and 2) greater release of silver ions occurs at lower pH. [32] [33] [34] The results showed both AION and AgNP have similar silver ion release profiles with minimal release (~ 0.1%) over 7 days per the case of DI water ( Fig. 2A ). No statistical significance was found between the release profiles. However, as seen from Fig To assess the effects of silver ion release, we examined the impact of AION on the viability of HepG2 and J774A.1 cells ( Fig. 2C and D) . These cells were incubated with AgNP and AION at two different concentrations (0.2 and 0.5 mg/ml of Ag) for 24 hours. The AION formulation was found to be biocompatible with both cell lines. However, when these cells were incubated with AgNP, their viability was significantly reduced compared to that of AION at each concentration. This result is in agreement with the observed silver ion release as more silver 10 ions were released from AgNP compared to AION. AgNP is a pure silver nanoparticle that is unstable towards oxidation and can release silver ions in biological conditions, which have previously been shown to cause cytotoxicity issues. 36 Overall, our hypothesis that use of Ag 2 S-NP would reduce silver ion release and improve biocompatibility of AION compared with pure silver nanoparticles was deemed correct.
Silver ion leaching and in vitro cell viability
Phantom imaging
We performed phantom imaging to evaluate the contrast generating properties of AION with the various breast imaging modalities. The DEM contrast properties of AION (at a concentration of 17 mg Ag/ml) were investigated using a step phantom. [37] [38] From Fig. 3A , it is evident that the background signal variations are removed and the contrast from AION is enhanced after DE subtraction. The signal difference-to-noise ratios (SDNR) calculated from the DE images indicate a significant increase in signal from background breast tissues when AION is present ( Fig. 3B ). 15, 20 Therefore, DEM imaging results indicated that AION is a suitable DEM contrast agent and that DEM subtraction can suppress the signal from the superimposing breast tissues and allow AION-containing breast tumors to be detected.
Since silver nanoparticles were previously shown to have CT attenuation properties, we expected similar results from AION. 20, 39 We evaluated the CT contrast properties of AION using a clinical CT imaging system. A CT phantom image of the different agents is presented in Fig.   3C . AION produce contrast that is linearly correlated with concentration, as is typical in CT ( Fig.   3D ). 40 Plots of CT attenuation versus concentration for all agents tested at each tube voltage are presented in Fig. S6 . Examination of the CT attenuation rates revealed that AION attenuate X-rays slightly less than iopamidol and nearly identically to silver nitrate as expected ( Fig. 3E ). A statistical significance was found between the CT attenuation rates of AION and iopamidol at each tube voltage as expected. Additionally, CT attenuation rates given in units of HU/mM are presented in Fig. S7 , where it can also be seen that AION produce slightly less contrast than 11 iopamidol. Notably, the CT attenuation rates of AION and iopamidol follow the same trend where the rates steadily decrease as the X-ray tube voltages increase from 80 to 140 kV. This is consistent with the fact that silver and iodine have k-edges (26 keV and 33 keV, respectively) that attenuate lower energy X-rays more strongly than higher energy X-rays. From these experiments, we conclude that AION produce CT contrast close to that of an iodinated agent and could serve as a CT contrast agent. Scale bar in units of radiant efficiency (x10 9 (p/s/cm 2 /sr)/µW/cm 2 ).
In vivo tumor imaging
The promising results from in vitro biocompatibility analyses and phantom imaging encouraged us to investigate the applicability of AION as a safe and effective contrast agent for in vivo breast cancer imaging. The in vivo imaging experiments were performed using mice inoculated with human breast cancer cells. After pre-injection scans were done, the mice were The average NIRF tumor-to-background ratio (TBR) significantly increased after injections of AION (Fig. 6C) . The TBRs at the 2 and 24 hour post-injection time points were not found to be significantly different. Overall, this result is in good agreement with the other contrast-enhanced imaging modalities as AION can readily improve breast tumor conspicuity in vivo. 
Biodistribution and pathology analysis
At 24 hours post-injection, animals were sacrificed and their organs and tumor tissues were collected for biodistribution analysis. The silver content in the tissues was determined using ICP-OES as shown in Fig. 7 . The results indicated that higher amounts of AION are taken up by the liver and spleen, which are the organs responsible for opsonization and reticuloendothelial phagocytosis. This finding is not atypical as other studies have reported similar results with comparable nanoparticle designs. [43] [44] Additionally, the animals did not show any adverse effects after injection with AION. Moreover, some degree of tumor accumulation is observed (more than 1% injected dose per gram of tissue), suggesting that the combination of surface PEGylation and particle size of AION facilitated their accumulation at the tumor site via the EPR effect. It is interesting to note that this level of tumor accumulation is sufficient to readily improve tumor conspicuity, at the dose used. Nevertheless, the design of AION could be modified to include higher molecular weight PEG ligands in order to provide more substantial stealth characteristics for evading the reticuloendothelial system (RES), thereby increasing the accumulation level of AION to further enhance contrast in tumors. [45] [46] To assess the in vivo safety of AION, we performed histopathological examination of organs (i.e. liver and spleen). Necropsy was performed at 24 hours after injection of AION at a dose of 250 mg Ag/kg and organs were fixed and stained with H&E for pathology analysis. As shown in Fig. S8 , no evident histopathological abnormalities or lesions were observed from the treated mice in comparison with the control. These preliminary findings support the in vivo safety of the AION contrast agent.
The sensitivity of conventional mammography is poor in women with dense breasts, primarily due to the masking effect from superimposing fibroglandular tissues. 2 Women with high breast density also have an increased chance of developing breast cancer, which is an inherent risk apart from issues related to screening. 5 These women are a vulnerable population and often require alternative screening methods for more accurate diagnosis of breast cancer.
Other imaging techniques such as contrast-enhanced DEM, CT, MRI, and NIRF imaging are being used or explored. These techniques are less affected by breast density and can highlight tumors via use of contrast agents. Several studies indicate that DEM and MRI have improved specificity and low false positive rates compared with conventional mammography, where the specificity is often limited, leading to unnecessary workups and benign biopsies. Furthermore, DEM has potentially better specificity than MRI due to linearity of contrast with agent concentration in X-ray imaging. [47] [48] [49] Some of these techniques are already being used clinically; however, they can vary widely in terms of cost, availability, and patient comfort. For instance, MRI is expensive, is not readily available, and is not applicable to patients with claustrophobia or contraindications such as pacemakers and metal implants. [50] [51] [52] More recently, gadolinium based contrast agents for MRI were found to accumulate in neural tissues even in subjects with normal renal function and remain there for a long time. [8] [9] [10] [11] The health effects from long-term retention of gadolinium in the brain are currently unknown. This finding provides incentive to develop alternative and improved contrast agents especially for women with elevated breast cancer risks as they commence screening in their 20s and continue for many years. Moreover, each of the imaging methods requires a different contrast agent, which can be problematic if supplemental screening is needed. The administration of multiple doses of agents can pose a safety concern as additional stress is being put on the body's clearance mechanisms. Therefore, it is highly advantageous to create a single probe that avoids the use of gadolinium or iodine based contrast agents to ensure safety and is functional for a variety of breast imaging modalities to provide flexibility in the diagnosis process. With the integration of several imaging modality agents, this multimodal nanoprobe could combine information from each individual imaging modality to provide complementary data, enhancing diagnostic specificity. 53 In this study, we developed AION as a multimodal contrast agent that improves tumor conspicuity with the aforementioned breast cancer imaging methods. AION are composed of two metal nanoparticles (i.e. IO-NP and Ag 2 S-NP) and a NIRF fluorophore (i.e. DiR). In particular, IO-NP generate T 2 contrast and are generally regarded to be safer and more biocompatible than gadolinium based nanoparticles due concern over the consequences of long-term gadolinium retention. 54 We chose Ag 2 S-NP as the material for DEM and CT contrast generation owing to their excellent biocompatibility that resulted from their very low solubility product. Ag 2 S-NP are also much lower in cost than gold-silver alloys (GSAN), a comparable DEM and CT agent. With the current metal prices (i.e. $0.55/g and $41.01/g for silver and gold, respectively), 55-56 the cost of a dose of 250 mg Ag/kg for a woman of average weight would be $10 for AION versus $330 for GSAN. The price would therefore be reduced by at least 30-fold with the use of silver sulfide-based agent (compared to GSAN with inclusion of 20% gold).
Furthermore, Ag 2 S-NP were previously shown to emit in the second NIR window (950-1350 nm), which is more desirable than the first NIR window due to lower photon absorption/scattering and tissue autofluorescence. 26, 57 This allows for imaging of deeper tissues and organs with enhanced signal-to-noise ratio. Therefore, it is possible to exclude DiR from the formulation and instead use Ag 2 S-NP to provide NIRF signal when NIR-II imaging systems become more widely available. 
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AION were shown to release a minimal amount of silver ions when incubated in both neutral and slightly acidic conditions. Of note, this study was performed without the use of any media that contains chloride ions, especially physiological buffers such as PBS or PBS with 10% serum. This is because the released silver ions can react with the chloride ions in the media to form silver chloride precipitates that are difficult to separate from the silver nanoparticles and be collected in the filtrate. The results for silver ion release may therefore be rendered inaccurate in such experiments. Interestingly, the overall cumulative silver ion release (%) in both conditions is substantially (at least five-fold) lower than that of PEG-thiol-coated silver nanoparticles (i.e. 0.7% in DI water and 2.5% in citrate buffer over 7 days). 20 This could be explained by the lipid coating of the nanoparticles preventing access to the silver nanoparticle surfaces. 27 Thus, we attributed the minimal silver ion release of AION to both the phospholipid coating and the low solubility of Ag 2 S-NP.
Our study has limitations, there was some level of elemental silver (or AION) accumulation in the liver and spleen after injection. Although this finding is not atypical, the surface PEGylation and particle size could be modified to slow their clearance by the RES and further increase their accumulation at the tumor site. As mentioned earlier, the inclusion of higher molecular weight PEG (e.g. 5k) on the particle surface could better deter opsonization and evade the RES. Moreover, decreasing the nanoparticle size from 200 nm might also improve tumor accumulation. 29 Notably, the contrast in the tumors was elevated over a range of time points. This could be beneficial for future clinical applications as AION can provide contrast for many hours after administration which eliminates the need for swift post-injection imaging as seen with current contrast agents, allowing for flexible scheduling and planning. Future directions for this platform might include the synthesis of ultra-small (< 5 nm) aqueous-phase silver based nanoparticles that can be swiftly excreted renally. This is advantageous as excretion from the body is an important criterion for FDA approval of a nanoparticle based contrast agent. Furthermore, these particles can be encapsulated in biodegradable polymeric nanoparticles for increased circulation time and enhanced tumor accumulation. 58 Lastly, AION are a promising contrast agent for DEM and may have use in the emerging technique of photon-counting spectral mammography. 59-60
Conclusion
In this study, we developed an "all-in-one" multimodal nanoparticle contrast agent for use by multiple breast cancer imaging techniques. AION were synthesized by incorporating Scanning electron microscopy and energy dispersive X-ray spectroscopy. To prepare for analysis, AION samples were drop casted onto an aluminum substrate and dried completely in a vacuum. An FEI Quanta 600 FEG scanning electron microscope operated at 20 kV and equipped with EDX spectrometry (EDAX, Inc.) was used to acquire SEM images and EDX spectra and line scan measurements of AION.
Dynamic light scattering and zeta potential. The hydrodynamic diameter and zeta potential of AION were measured using a Nano ZS-90 Zetasizer (Malvern instrument, UK). In brief, 10 µl of AION from the stock were diluted with 2 ml of DI water. 1.5 ml and 1 ml of nanoparticle suspension were used for the measurement of hydrodynamic diameter and zeta potential, respectively. The number mean was reported for the hydrodynamic diameter. All measurements were performed at 25 °C. Equation (1) Computed tomography. The CT phantom was constructed according to a previously reported method. 40 In brief, different concentrations (0.5 to 10 mg/ml, diluted with DI water) of iopamidol, AgNO 3 , and AION were placed into PCR tubes that were later secured in a plastic rack.
Negative controls were prepared using DI water and PBS. The phantom included three replicates for each concentration and each agent. The rack was immersed in water (21 cm in height) and scanned with a Siemens SOMATOM Force clinical CT scanner at 80, 100, 120, and 140 kV. The images were acquired using the following parameters: tube current = 360 mA, matrix size = 512 x 512, slice thickness = 0.5 cm, field of view (FOV) = 37 x 37 cm. Osirix 64 bit was used to determine the attenuation values in Hounsfield units (HU) for each sample tube using the ROI analysis tool. CT attenuation rates (HUml/mg and HU/mM) were calculated for each agent at each voltage and presented as mean ± SD. Biodistribution. Tumor-bearing mice were sacrificed at 24 hours after injection and their blood samples were then collected. After the left ventricle was perfused with PBS, the liver, lungs, heart, spleen, kidneys, tumors and feces were collected. The organs and tumors were first weighed and minced into small pieces that were then digested in 2 ml of concentrated nitric acid at 75 °C for 16 hours. The digested samples were made to 10 ml with DI water for subsequent measurement of silver concentration via ICP-OES. Data are presented as mean ± SEM.
Pathology analysis. Non tumor-bearing mice (n = 4 per group) were sacrificed at 24 hours after injection of PBS (vehicle control) or AION at a dose 250 mg Ag/kg (the same volume was used in each case). After the left ventricles were perfused with PBS, the livers and spleens were collected. The organs were briefly washed with cold PBS and cut into small pieces with thickness of 5 to 6 mm. The organ pieces were then fixed in 10% neutral buffered formalin and dehydrated with ethanol. Subsequently, tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E) for histological examination. The stained slices were analyzed with a light microscope (Nikon).
Statistical analysis.
All experiments were carried out in triplicate at the least, or in three independent experiments. Statistical analyses were performed via two-tailed Student's t-tests
using GraphPad Prism 6 software.
